Eye Co is a privately held company investing in early stage development of anti-inflammatory based therapeutics to prevent retinal blindness.

Eye Co’s goal is to out-license its IP for these therapeutics to global pharma groups with the resources to complete development and commercialisation.

Our Business

The global ophthalmology market is valued in excess of US$20B in annual sales. Key market drivers include an aging population as well as changes in diet and lifestyle globally leading to increases in diabetes and other metabolic disorders resulting in associated increases in disorders of the eye frequently leading to blindness.

These increasingly prevalent pathologies, resulting in part from the rapidly increasing incidence of age-related onset of diabetes in both the developed and developing world, are among the fastest growing causes of blindness.

Eye Co Pty Ltd.’s principal business activity is the early stage research and development of technologies for the treatment of diseases of the retina of the eye and the commercialization, marketing, and sale of the resultant products in Australia and internationally by globally capable third party partners.

Most recently, Eye Co commissioned a Phase 1b safety study in humans to ascertain the safety of its mineralocorticoid technology in the treatment of Geographic Atrophy associated with dry Age Related Macular Degeneration ( d-AMD).